Skip to main content
. 2010 Oct 29;5(10):e13710. doi: 10.1371/journal.pone.0013710

Figure 5. Effect of PF4-DLR + siRNA ILK1 treatment on glioblastomas development in vivo.

Figure 5

A) Representative hematoxylin-eosin stained histological sections of brains from mice xenografted with U87-MG and treated or not (NT) with PF4-DLR or PF4-DLR plus ILK1 siRNA (PF4-DLR + siRNA ILK1). Scale bar  = 1 mm. B) Tumor volumes were quantified from six different brains per group, and the results expressed as mean values ± SEM. Significant differences between groups are indicated (one-way ANOVA followed by Tukey's post hoc test, **p< 0.05 PF4-DLR versus NT; §§p< 0.05 PF4-DLR + siRNA ILK1 versus PF4-DLR). C) Representative image of vessel staining (blue: DAPI, red: anti CD31) and immunohistochemestry of CD31. Scale bar 20 µm. D) Vessels were counted in the tumor area and were found significantly reduced in animals treated with PF4-DLR or PF4-DLR plus ILK1 siRNA (PF4-DLR + siRNA ILK1). Significant differences between groups are indicated (one-way ANOVA followed by Tukey's post hoc test **p<0.05 PF4-DLR versus NT; §§p<0.05 PF4-DLR + siRNA ILK1 versus PF4-DLR).